Screener
MapLight Therapeutics, Inc. MPLT Preclinical Program — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by MapLight Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: MapLight Therapeutics, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:25 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-224129
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Clinical trial expenses | $24,819 | $1,939 |
| Employee-related research and development expenses | 15,993 | 7,050 |
| Chemistry, manufacturing and controls expenses | 6,417 | 3,956 |
| Preclinical program expenses | 5,522 | 6,081 |
| Other research and development expenses | 933 | 761 |
| Employee-related general and administrative expenses | 6,990 | 2,060 |
| Professional fees and other general and administrative expenses | 3,829 | 1,696 |
| Other segment items(1) | (3,835) | (1,203) |
Item 1. Financial Statements.
FAQ
- What is MapLight Therapeutics, Inc.'s preclinical program — research and development expense?
- MapLight Therapeutics, Inc. (MPLT) reported preclinical program — research and development expense of $5.52M in Q1 2026.
- How has MapLight Therapeutics, Inc.'s preclinical program — research and development expense changed year-over-year?
- MapLight Therapeutics, Inc.'s preclinical program — research and development expense decreased by 9.2% year-over-year, from $6.08M to $5.52M.
- What does preclinical program — research and development expense mean?
- This metric represents the total operating costs directly attributable to the research and development activities within the company's preclinical-stage pipeline. It captures expenditures related to early-stage drug discovery, laboratory testing, and initial feasibility studies before a candidate enters formal clinical trials. Monitoring this expense provides insight into the company's commitment to innovation and the pace at which it advances its early-stage therapeutic portfolio.
Ask your AI about MapLight Therapeutics, Inc.'s preclinical program — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude